D Montgomery Bissell1, Jennifer C Lai2, Raymond K Meister3, Paul D Blanc4. 1. Division of Gastroenterology, Department of Medicine, University of California, San Francisco. Electronic address: montgomery.bissell@ucsf.edu. 2. Division of Gastroenterology, Department of Medicine, University of California, San Francisco. 3. Occupational Lead Poisoning Prevention Program, California Department of Public Health, Richmond. 4. Division of Occupational and Environmental Medicine, Department of Medicine, University of California, San Francisco.
Abstract
BACKGROUND: Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen. The basis for the acute symptoms in these diseases has been speculative. METHODS: We review genetic acute porphyria, hereditary tyrosinemia, and an acquired condition, lead poisoning. All perturb heme synthesis and present with a similar pain syndrome. RESULTS: Although each of these conditions has characteristic urine biochemistry, all exhibit excess delta-aminolevulinic acid. Moreover, in all, treatment with hemin reduces delta-aminolevulinic acid and relieves symptoms. In contrast, use of recombinant porphobilinogen deaminase to knock down porphobilinogen in acute porphyria was ineffective. CONCLUSIONS: There is now convincing evidence that delta-aminolevulinic acid is the cause of pain in the acute porphyrias. The efficacy of hemin infusion is due mainly, if not entirely, to its inhibition of hepatic delta-aminolevulinic acid synthase-1, the enzyme that catalyzes delta-aminolevulinic acid formation. Delta-aminolevulinic acid synthase-1 is a rational target for additional therapies to control symptoms in acute porphyria.
BACKGROUND: Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen. The basis for the acute symptoms in these diseases has been speculative. METHODS: We review genetic acute porphyria, hereditary tyrosinemia, and an acquired condition, lead poisoning. All perturb heme synthesis and present with a similar pain syndrome. RESULTS: Although each of these conditions has characteristic urine biochemistry, all exhibit excess delta-aminolevulinic acid. Moreover, in all, treatment with hemin reduces delta-aminolevulinic acid and relieves symptoms. In contrast, use of recombinant porphobilinogen deaminase to knock down porphobilinogen in acute porphyria was ineffective. CONCLUSIONS: There is now convincing evidence that delta-aminolevulinic acid is the cause of pain in the acute porphyrias. The efficacy of hemin infusion is due mainly, if not entirely, to its inhibition of hepatic delta-aminolevulinic acid synthase-1, the enzyme that catalyzes delta-aminolevulinic acid formation. Delta-aminolevulinic acid synthase-1 is a rational target for additional therapies to control symptoms in acute porphyria.
Authors: Karl E Anderson; Joseph R Bloomer; Herbert L Bonkovsky; James P Kushner; Claus A Pierach; Neville R Pimstone; Robert J Desnick Journal: Ann Intern Med Date: 2005-03-15 Impact factor: 25.391
Authors: Robert B Saper; Russell S Phillips; Anusha Sehgal; Nadia Khouri; Roger B Davis; Janet Paquin; Venkatesh Thuppil; Stefanos N Kales Journal: JAMA Date: 2008-08-27 Impact factor: 56.272
Authors: Michael J Kosnett; Richard P Wedeen; Stephen J Rothenberg; Karen L Hipkins; Barbara L Materna; Brian S Schwartz; Howard Hu; Alan Woolf Journal: Environ Health Perspect Date: 2006-12-22 Impact factor: 9.031
Authors: Chaudry Nasir Majeed; Christopher D Ma; Ted Xiao; Sean Rudnick; Herbert L Bonkovsky Journal: Drug Des Devel Ther Date: 2022-06-16 Impact factor: 4.319
Authors: Bradford M Stubenhaus; John P Dustin; Emily R Neverett; Megan S Beaudry; Leanna E Nadeau; Ethan Burk-McCoy; Xinwen He; Bret J Pearson; Jason Pellettieri Journal: Elife Date: 2016-05-31 Impact factor: 8.140